Atlas FDA

Predicate Research Report · generated 2026-08-22 · Print / save as PDF · Save to account

Cozart Bioscience , Ltd. — Predicate Candidate Screening

6 FDA 510(k) clearances under this manufacturer; the 50 most recent screened below.

188 daysmedian FDA review time
335 days90th percentile
6clearances measured
K-numberDeviceApplicantDecidedReview daysRecalls (K-match)
K033743COZART EIA AMPHETAMINES ORAL FLUID MICROPLATE KITCozart Bioscience , Ltd.2004-06-031880
K021944COZART EIA COTININE URINE KITCozart Bioscience , Ltd.2003-05-143350
K030234COZART EIA COCAINE ORAL FLIUD KITCozart Bioscience , Ltd.2003-04-28950
K024339COZART EIA OPIATES ORAL FLUID KITCozart Bioscience , Ltd.2003-04-071010
K020920COZART RAPISCAN ORAL FLUID DRUG TEST - OPIATE/METHADONECozart Bioscience , Ltd.2002-11-052290
K011131METHADONE MICROPLATE EIA URINE APPLICATIONCozart Bioscience , Ltd.2001-07-311090

Methodology

Recall counts reflect FDA recall records explicitly referencing each K-number; FDA links recalls to K-numbers inconsistently, so 0 means "none found in FDA records," not "never recalled." Data: FDA openFDA, refreshed weekly. Verify decisions of consequence against the primary source. Full candidate set and CSV export: atlasbyauro.com.

Prepared with Atlas

Predicate research, review-time statistics and recall monitoring for 510(k) teams — atlasbyauro.com/fda